Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04407611 · ClinicalTrials.gov registry record · NA
Scalable Communication Modalities for Returning Genetic Research Results
A NA study of Lynch Syndrome and Hereditary Breast and Ovarian Cancer, sponsored by Boston University.
- Active
- Registry status
- NA
- Development phase
- 932
- Enrollment target
- 1
- Study location
NCT04407611: Active NA study of Lynch Syndrome and Hereditary Breast and Ovarian Cancer, sponsored by Boston University.
NCT04407611 is a NA study of Lynch Syndrome and Hereditary Breast and Ovarian Cancer that is active but no longer recruiting, run by Boston University. The registered enrollment target is 932 participants, below the 2,272-participant average among 21 other Lynch Syndrome trials with a reported enrollment target (59% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04407611, a NA study of Lynch Syndrome and Hereditary Breast and Ovarian Cancer, is active but no longer recruiting, sponsored by Boston University.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 932 participants
- Enrollment target
- 1
- Study location
Study Summary
Efforts to examine the utility of alternate modalities for genetic results disclosure has widespread implications for how precision medicine research might yield direct health benefits for study participants. This study will examine the efficacy of an online self-guided program to return genetic results to a racial minority cohort population. Study results will provide empirical evidence on the effectiveness of alternate modalities for genetic results return, inform ongoing efforts to establish scalable approaches for effective return of genetic research results, and increase access to personal health information among African American women.
Primary Outcome
Decisions about learning genetic results for hereditary breast and ovarian cancer will be monitored and recorded in the electronic study database system.
Conditions Studied
Interventions
- BEHAVIORAL Online modality
- BEHAVIORAL Genetic counselor follow-up
Study Locations (1)
Massachusetts
- BU School of Public Health, the research is being conducted remotely - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 932 participants |
| Start Date | 2023-03-06 |
| Est. Completion | 2026-03 |
| Phase | NA |
What the registry record for NCT04407611 still lists
NCT04407611 is an interventional study that assigns participants to a tested intervention. The registered 932 participants enrollment target is mid-sized for trials with a published cap, below the 2,272-participant average among 21 other Lynch Syndrome trials with a reported enrollment target (59% lower).
The record links to 2 conditions, with Lynch Syndrome appearing as the primary indexed condition, and to 2 interventions - of which Online modality is the first listed.
NCT04407611 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04407611 about?
NCT04407611 is a clinical study titled "Scalable Communication Modalities for Returning Genetic Research Results". Efforts to examine the utility of alternate modalities for genetic results disclosure has widespread implications for how precision medicine research might yield direct health benefits for study participants. This study will examine the efficacy of an online self-guided program to return genetic res...
What is the current status of trial NCT04407611?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 932 participants. The study started on 2023-03-06. Estimated completion is 2026-03.
What conditions does trial NCT04407611 study?
This clinical trial studies the following conditions: Lynch Syndrome, Hereditary Breast and Ovarian Cancer.
What interventions are being tested in trial NCT04407611?
The interventions under investigation include: Online modality (BEHAVIORAL), Genetic counselor follow-up (BEHAVIORAL).
Who is sponsoring clinical trial NCT04407611?
This trial is sponsored by Boston University, which has 185 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04407611 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lynch Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04407611's enrollment target sits among peer trials
932 5th of 21 higher than 17 of 21 other Lynch Syndrome trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lynch Syndrome trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Identifying and Caring for Individuals With Inherited Cancer Syndrome
RECRUITING · NA
-
A Study for Imaging the Lower Gastrointestinal Tract Using a Retro-TCE Capsule
RECRUITING · NA
-
Menstrual Cup for Early Endometrial Cancer Detection in Lynch Syndrome
RECRUITING · NA
-
Feasibility Study: IGNITE-TX (Identifying Individuals for Genetic Testing & Treatment) Intervention
ACTIVE NOT RECRUITING · NA
-
Weight Management and Health Behavior Intervention in Lowering Cancer Risk for BRCA Positive and Lynch Syndrome Families
ACTIVE NOT RECRUITING · NA
-
Energy Balance Interventions in Increasing Physical Activity in Breast Cancer Gene Positive Patients, Lynch Syndrome-Positive Patients, CLL Survivors or High-Risk Family Members
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04626635 · 933 participants · Phase 1
A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers
- NCT05216432 · 930 participants · Phase 1
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
- NCT06932029 · 930 participants · NA
SMBP Study: Improving High Blood Pressure in Older Adults With Multiple Chronic Diseases
- NCT07235085 · 930 participants · Phase 3
A Study to Evaluate the Efficacy and Safety of OTX-TKI (Axitinib Implant) in Participants With Non-Proliferative Diabetic Retinopathy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI